Related Experiment Video

Updated: Aug 13, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Is Cyclin D1-CDK4 kinase a bona fide cancer target?

Marcos Malumbres1, Mariano Barbacid

  • 1Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid E-28029, Spain. malumbres@cnio.es

Cancer Cell
|January 18, 2006
PubMed

Insights

Mice lacking Cyclin D1 resist mammary tumors driven by HER-2. Inactivating Cyclin D1-Cdk4/6 kinases may offer a new cancer therapy strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Cycle Regulation

Background:

  • Cyclin D1 is crucial for cell cycle progression and has been implicated in various cancers.
  • The HER-2 (Human Epidermal growth factor Receptor 2) oncogene, a driver of many breast carcinomas, is linked to Cyclin D1 activity.
  • Previous research indicated a link between Cyclin D1 deficiency and resistance to HER-2-induced mammary tumors in mice.

Discussion:

  • Two new studies investigate the role of Cyclin D1 and its interaction with Cyclin-dependent kinases (CDKs) in mammary tumorigenesis.
  • Experiments using knockin mice with a non-activating Cyclin D1 mutant demonstrate resistance to HER-2-driven tumor formation.
  • Direct knockdown of Cdk4 in existing mammary tumor cells effectively halts tumor growth, reinforcing the kinase's oncogenic role.

Key Insights:

  • Cyclin D1's catalytic activity, not just its binding to Cdk4/6, is essential for HER-2-induced mammary tumorigenesis.
  • The Cyclin D1-Cdk4/6 kinase complex is a critical mediator of HER-2 oncogenic signaling in mammary epithelial cells.
  • Targeting the Cyclin D1-Cdk4/6 pathway presents a promising therapeutic strategy for HER-2-positive breast cancers.

Outlook:

  • Further research is warranted to explore the therapeutic potential of inhibiting Cyclin D1-Cdk4/6 kinases in clinical settings.
  • Developing specific inhibitors targeting the Cyclin D1-Cdk4/6 complex could lead to novel treatments for HER-2-driven cancers.
  • Understanding the precise mechanisms of Cyclin D1-Cdk4/6 in tumorigenesis may reveal new therapeutic vulnerabilities.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...